چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| علی اکبر موثق پور اکبری | سوم |
| نسرین غلامی | اول |
| آرزو فتحعلی زاده | دوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Abstract 9 CD38 level of newly diagnosed AML patients and their overall survival Nasrin Gholami1, Arezoo Fathalizadeh1, Aliakbar Movasaghpour1 1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Introduction: Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. The overall 5-year survival in AML patients over 65 years of age is less than 5%. Studies have shown that increasing the expression of some membrane molecules such as CD25, CD40, and CD11a are effective in poor prognosis of AML detection. Among membrane molecules, CD38 is a membrane glycoprotein that can act as a site for CD31 binding or an ecoenzyme involved in NAD + and NADP catabolism. In this study, the CD38 level of expression in patients and its relationship with the prognosis of the disease will be examined to be used as a prognostic factor. Materials and Methods: All the newly diagnosed nonM3 AML patients referred to Shahid Ghazi Tabatabai Hospital, Tabriz, Iran, in 4 years (2017 – 2021) were included in this study. Patients’ disease had been confirmed by flow cytometry of bone marrow samples. Bone marrow samples were preparated as a suspension and then cell concentration was modulated. Flowcytometry was performed using BD FACS callibur device and cell guest software. Using the BD FACS callibur system and a dedicated panel that will be used directly against specific class antigens, especially CD38. Results: Seventy two newly diagnosed AML patients were followed in this study. Of them 45.8% (n=33) were male and 33.3 % (n=24) were older than 60 years with the mean age of 50.29 ± 18.38. CD38 expression mean was 84.21% (± 16.35). Overall survival was 37.5% with the mean of 336.41 days (95% CI; 249.87 -422.95) and median 219 days. Log rank test of equality of survival distributions for the different levels of CD38 showed that there was a significant relationship between overall survival and CD38 levels. Cox-regression analysis showed that increasing of CD38 level by 1% increased the hazard of mortality by 1 percent (HR=0.99; 95% CI: 0.98 to 1.01). One year survival rate was 18% (95% CI; 0.08 to 0.31) and there was significant relationship between CD38 levels and one year survival rates (P=0.0002). However Stratified log-rank test for equality of survivor functions adjusted for CD38 level, revealed that one-year survival rates were significantly associated with age (P=0.0006) and gender(P= 0.0001)of AML patients. Female and ≥60 years old patients had significantly lower one-year survival rates. Conclusions: There was a significant relationship between CD38 levels and one year survival rates in newly diagnosed AML patients. Keywords: CD38, AML, Overall Survival |
| کلمات کلیدی | CD38, AML, Overall Survival |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| article (1).pdf | 1402/12/20 | 766372 | دانلود |
| book.pdf | 1402/12/20 | 7027930 | دانلود |
| Abstract 2.docx | 1402/12/21 | 332950 | دانلود |
